| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K/A |
| Revenues: |
| Mobile Labs | 4.8 | 5.0 | | | | | | |
| Medical Devices | 0.4 | 0.4 | | | | | | |
| Molecular Diagnostics | 0.1 | 0.1 | | | | | | |
| ID Security | | | | | | | | 3.0 |
| Total revenues | 5.4 | 5.6 | 2.9 | 0.9 | 0.0 | 0.0 | 0.0 | 0.1 |
| Revenue growth [+] | -3.6% | 89.1% | 211.1% | | | | -100.0% | -78.8% |
| Mobile Labs | -4.4% | | | | | | | |
| Medical Devices | -1.4% | | | | | | | |
| Molecular Diagnostics | 23.5% | | | | | | | |
| ID Security | | | | | | | | 1480.1% |
| HealthID | | | | | | | | -53.7% |
| Cost of goods sold | 3.5 | 3.5 | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 1.8 | 2.0 | 2.6 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 34.4% | 36.4% | 88.6% | 68.9% | | | | 40.0% |
| Selling, general and administrative | 5.8 | 8.7 | 5.6 | 4.3 | 4.3 | 6.5 | 10.8 | 9.7 |
| Research and development | 0.5 | 0.4 | 1.4 | 0.6 | 0.7 | 0.9 | 0.8 | 1.4 |
| Other operating expenses | | | | | | | 4.3 | -1.6 |
| EBITDA [+] | -4.3 | -6.8 | -4.2 | -4.0 | -4.6 | -7.0 | -15.7 | -9.5 |
| EBITDA growth | -37.2% | 64.3% | 5.2% | -13.5% | -34.3% | -55.6% | 65.8% | -41.0% |
| EBITDA margin | -80.2% | -123.2% | -141.8% | -419.3% | | | | -12614.7% |
| Depreciation | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 |
| EBITA | -4.3 | -6.9 | -4.2 | -4.0 | -5.0 | -7.0 | -15.7 | -9.5 |
| EBITA margin | -81.1% | -123.9% | -141.9% | -420.4% | | | | -12648.0% |
| Amortization of intangibles | 0.2 | 0.3 | 0.3 | 0.3 | | 0.4 | 0.2 | |
| EBIT [+] | -4.5 | -7.1 | -4.4 | -4.3 | -5.0 | -7.4 | -16.0 | -9.5 |
| EBIT growth | -37.0% | 61.5% | 4.1% | -14.2% | -33.1% | -53.6% | 68.2% | -40.9% |
| EBIT margin | -84.0% | -128.6% | -150.5% | -449.7% | | | | -12648.0% |
| Non-recurring items [+] | 0.3 | | | | | 0.4 | 0.6 | 1.6 |
| Asset impairment | 0.3 | | | | | 0.4 | 0.6 | 1.6 |
| Interest expense | 3.7 | 7.7 | 4.7 | 3.0 | 0.6 | 0.2 | | |
| Interest expense | 3.7 | 7.7 | 4.7 | 3.0 | 0.6 | 0.2 | | |
| Other income (expense), net [+] | -0.2 | 1.7 | -2.3 | 0.1 | 1.6 | -0.1 | 0.1 | 0.0 |
| Gain (loss) on debt retirement | 0.0 | 0.0 | | -0.2 | | | | |
| Change in value of contingent liability | | 0.1 | | | | | | |
| Other non-operating income | | | | | | | 0.1 | |
| Other | 0.0 | 0.1 | 0.4 | 0.0 | -1.5 | -0.1 | 0.1 | 0.0 |
| Pre-tax income | -8.7 | -13.1 | -11.4 | -7.2 | -4.0 | -8.0 | -16.4 | -11.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.1 | 4.9 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | 0.0% | | |
| Minority interest | 0.2 | | | | | | | |
| Net income | -8.9 | -13.2 | -11.5 | -8.2 | -13.3 | -25.3 | -16.7 | -16.1 |
| Net margin | -166.3% | -237.7% | -391.5% | -870.2% | | | | -21424.0% |
| |
| Basic EPS [+] | ($0.15) | ($167.53) | ($1.88) | ($85.12) | ($0.71) | ($4.60) | ($0.43) | ($0.67) |
| Growth | -99.9% | 8814.7% | -97.8% | 11865.4% | -84.5% | 961.1% | -35.2% | -25.4% |
| Diluted EPS [+] | ($0.15) | ($167.53) | ($1.88) | ($85.12) | ($0.71) | ($4.60) | ($0.43) | ($0.67) |
| Growth | -99.9% | 8814.7% | -97.8% | 11865.4% | -84.5% | 961.1% | -35.2% | -25.4% |
| |
| Shares outstanding (basic) [+] | 57.8 | 0.1 | 6.1 | 0.1 | 18.7 | 5.5 | 38.5 | 24.0 |
| Growth | 73198.8% | -98.7% | 6240.3% | -99.5% | 241.1% | -85.7% | 60.5% | 84.2% |
| Shares outstanding (diluted) [+] | 57.8 | 0.1 | 6.1 | 0.1 | 18.7 | 5.5 | 38.5 | 24.0 |
| Growth | 73198.8% | -98.7% | 6240.3% | -99.5% | 241.1% | -85.7% | 60.5% | 84.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |